Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control

Breast cancer (BC) remains the second most common cause of cancer-related deaths in women in the US, despite advances in detection and treatment. In addition, breast cancer survivors often struggle with long-term treatment related comorbidities. Identifying novel therapies that are effective while m...

Full description

Saved in:
Bibliographic Details
Main Authors: Meenakshi Sudhakaran (Author), Sagar Sardesai (Author), Andrea I. Doseff (Author)
Format: Book
Published: MDPI AG, 2019-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_439a9a00b4904a42961dfa6b7affb32b
042 |a dc 
100 1 0 |a Meenakshi Sudhakaran  |e author 
700 1 0 |a Sagar Sardesai  |e author 
700 1 0 |a Andrea I. Doseff  |e author 
245 0 0 |a Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control 
260 |b MDPI AG,   |c 2019-04-01T00:00:00Z. 
500 |a 2076-3921 
500 |a 10.3390/antiox8040103 
520 |a Breast cancer (BC) remains the second most common cause of cancer-related deaths in women in the US, despite advances in detection and treatment. In addition, breast cancer survivors often struggle with long-term treatment related comorbidities. Identifying novel therapies that are effective while minimizing toxicity is critical in curtailing this disease. Flavonoids, a subclass of plant polyphenols, are emerging as promising treatment options for the prevention and treatment of breast cancer. Recent evidence suggests that in addition to anti-oxidant properties, flavonoids can directly interact with proteins, making them ideal small molecules for the modulation of enzymes, transcription factors and cell surface receptors. Of particular interest is the ability of flavonoids to modulate the tumor associated macrophage function. However, clinical applications of flavonoids in cancer trials are limited. Epidemiological and smaller clinical studies have been largely hypothesis generating. Future research should aim at addressing known challenges with a broader use of preclinical models and investigating enhanced dose-delivery systems that can overcome limited bioavailability of dietary flavonoids. In this review, we discuss the structure-functional impact of flavonoids and their action on breast tumor cells and the tumor microenvironment, with an emphasis on their clinical role in the prevention and treatment of breast cancer. 
546 |a EN 
690 |a cancer therapeutics 
690 |a cancer prevention 
690 |a metastasis 
690 |a chemoprevention 
690 |a flavonoids 
690 |a immune-regulation 
690 |a apigenin 
690 |a obesity 
690 |a foods for health 
690 |a inflammation 
690 |a macrophages 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antioxidants, Vol 8, Iss 4, p 103 (2019) 
787 0 |n https://www.mdpi.com/2076-3921/8/4/103 
787 0 |n https://doaj.org/toc/2076-3921 
856 4 1 |u https://doaj.org/article/439a9a00b4904a42961dfa6b7affb32b  |z Connect to this object online.